Financial Ratios

SUVEN PHARMACEUTICALS LTD.

NSE : SUVENPHARBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE671.201.7 (+0.25 %)
PREV CLOSE ( ) 669.50
OPEN PRICE ( ) 670.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1762
TODAY'S LOW / HIGH ( )658.50 674.55
52 WK LOW / HIGH ( )427.05 767
NSE672.102.5 (+0.37 %)
PREV CLOSE( ) 669.60
OPEN PRICE ( ) 670.00
BID PRICE (QTY) 672.10 (5)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 157209
TODAY'S LOW / HIGH( ) 657.00 674.90
52 WK LOW / HIGH ( )469.45 768
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)16.9921.9212.1221.220.00
   CEPS(Rs)18.6823.4613.3711.53
   DPS(Rs)6.005.002.005.000.00
   Book NAV/Share(Rs)68.7259.7441.8461.50
   Tax Rate(%)25.3422.7525.4424.4730.78
Margin Ratios
   Core EBITDA Margin(%)44.3544.0843.8846.1545.40
   EBIT Margin(%)44.4855.3342.1545.5042.52
   Pre Tax Margin(%)43.5254.6841.0042.8941.78
   PAT Margin (%)32.5042.2430.5732.3928.92
   Cash Profit Margin (%)35.7145.2033.7035.2131.96
Performance Ratios
   ROA(%)21.3932.8022.9426.4013.39
   ROE(%)26.4643.1733.4039.7118.92
   ROCE(%)34.4851.7939.1546.2323.87
   Asset Turnover(x)0.660.780.750.810.46
   Sales/Fixed Asset(x)1.892.091.972.071.09
   Working Capital/Sales(x)1.661.472.934.361.63
Efficiency Ratios
   Fixed Capital/Sales(x)0.530.480.510.480.92
   Receivable days47.4446.8039.6957.94142.49
   Inventory Days81.5566.9367.9572.66151.76
   Payable days77.7087.4594.44100.95192.73
Valuation Parameters
   PER(x)27.8228.1940.864.75
   PCE(x)25.3126.3437.068.73
   Price/Book(x)6.8810.3411.843.28
   Yield(%)1.270.810.402.48
   EV/Net Sales(x)9.0611.9612.623.28
   EV/Core EBITDA(x)18.9920.5127.876.79
   EV/EBIT(x)20.3621.6129.947.21
   EV/CE(x)6.639.7710.562.83
   M Cap / Sales9.0511.9212.493.08
Growth Ratio
   Net Sales Growth(%)0.7530.7521.10120.680.00
   Core EBITDA Growth(%)-17.5468.4013.49134.040.00
   EBIT Growth(%)-18.9971.7312.19136.160.00
   PAT Growth(%)-22.4980.8214.28147.160.00
   EPS Growth(%)-22.4980.82-42.86
Financial Stability Ratios
   Total Debt/Equity(x)0.040.060.130.240.14
   Current Ratio(x)3.683.602.071.602.22
   Quick Ratio(x)2.642.781.451.051.39
   Interest Cover(x)46.4585.7236.4917.3957.60
   Total Debt/Mcap(x)0.010.010.010.07

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.